| Dr Nickie Spears, MD | |
|
1241 N Main St, Harrisonburg, VA 22802 | |
| (540) 434-1941 | |
| (540) 434-0132 |
| Full Name | Dr Nickie Spears |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 35 Years |
| Location | 1241 N Main St, Harrisonburg, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962689745 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 0101045827 (Virginia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Harrisonburg-rockingham Community Services Board | 1052202884 | 10 |
News Archive
In a clinical trial, a self-expanding transcatheter aortic valve met the key performance objective of reducing death and stroke in patients with severe aortic stenosis at "extreme risk" for surgery.Results of the COREVALVE EXTREME RISK trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
A team of scientists from Israel has recently evaluated the efficacy of an mRNA-based coronavirus disease 2019 (COVID-19) vaccine, BNT162b2, in inducing host humoral immune response. The findings reveal that the vaccine is capable of inducing strong anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response and that the response varies significantly with age. The study is currently available on the medRxiv* preprint server.
The new strain, ST131, was a major cause of serious antimicrobial-resistant E. coli infections in the United States in 2007, researchers found. This strain has been reported in multiple countries and encountered all over the United States. In the study, researchers analyzed resistant E. coli isolates collected during 2007 from hospitalized patients across the country. They identified 54 ST131 isolates, which accounted for 67 percent to 69 percent of E. coli isolates exhibiting fluoroquinolone or extended-spectrum cephalosporin resistance.
VIVUS, Inc. today announced that phase 3 data on avanafil, a next generation oral phosphodiesterase type 5 inhibitor therapy being investigated for the treatment of erectile dysfunction, will be presented next Tuesday at the American Urological Association 2010 Annual Meeting in San Francisco, California.
MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants representing total funding of $9.8 million.
› Verified 3 days ago
| Entity Name | Harrisonburg-rockingham Community Services Board |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215933817 PECOS PAC ID: 1052202884 Enrollment ID: O20040322001677 |
News Archive
In a clinical trial, a self-expanding transcatheter aortic valve met the key performance objective of reducing death and stroke in patients with severe aortic stenosis at "extreme risk" for surgery.Results of the COREVALVE EXTREME RISK trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
A team of scientists from Israel has recently evaluated the efficacy of an mRNA-based coronavirus disease 2019 (COVID-19) vaccine, BNT162b2, in inducing host humoral immune response. The findings reveal that the vaccine is capable of inducing strong anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response and that the response varies significantly with age. The study is currently available on the medRxiv* preprint server.
The new strain, ST131, was a major cause of serious antimicrobial-resistant E. coli infections in the United States in 2007, researchers found. This strain has been reported in multiple countries and encountered all over the United States. In the study, researchers analyzed resistant E. coli isolates collected during 2007 from hospitalized patients across the country. They identified 54 ST131 isolates, which accounted for 67 percent to 69 percent of E. coli isolates exhibiting fluoroquinolone or extended-spectrum cephalosporin resistance.
VIVUS, Inc. today announced that phase 3 data on avanafil, a next generation oral phosphodiesterase type 5 inhibitor therapy being investigated for the treatment of erectile dysfunction, will be presented next Tuesday at the American Urological Association 2010 Annual Meeting in San Francisco, California.
MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants representing total funding of $9.8 million.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nickie Spears, MD 1241 N Main St, Harrisonburg, VA 22802-4632 Ph: (540) 434-1941 | Dr Nickie Spears, MD 1241 N Main St, Harrisonburg, VA 22802 Ph: (540) 434-1941 |
News Archive
In a clinical trial, a self-expanding transcatheter aortic valve met the key performance objective of reducing death and stroke in patients with severe aortic stenosis at "extreme risk" for surgery.Results of the COREVALVE EXTREME RISK trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
A team of scientists from Israel has recently evaluated the efficacy of an mRNA-based coronavirus disease 2019 (COVID-19) vaccine, BNT162b2, in inducing host humoral immune response. The findings reveal that the vaccine is capable of inducing strong anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response and that the response varies significantly with age. The study is currently available on the medRxiv* preprint server.
The new strain, ST131, was a major cause of serious antimicrobial-resistant E. coli infections in the United States in 2007, researchers found. This strain has been reported in multiple countries and encountered all over the United States. In the study, researchers analyzed resistant E. coli isolates collected during 2007 from hospitalized patients across the country. They identified 54 ST131 isolates, which accounted for 67 percent to 69 percent of E. coli isolates exhibiting fluoroquinolone or extended-spectrum cephalosporin resistance.
VIVUS, Inc. today announced that phase 3 data on avanafil, a next generation oral phosphodiesterase type 5 inhibitor therapy being investigated for the treatment of erectile dysfunction, will be presented next Tuesday at the American Urological Association 2010 Annual Meeting in San Francisco, California.
MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants representing total funding of $9.8 million.
› Verified 3 days ago
Dr. Glenn E Deputy, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1871 Evelyn Byrd Ave, Harrisonburg, VA 22801 Phone: 540-564-5800 Fax: 540-564-5801 | |
Thomas William Hester, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1241 N Main St, Harrisonburg, VA 22802 Phone: 541-434-1941 | |
Syed Shamshad Ali Rizvi, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 136 W Elizabeth St Ste 102, Harrisonburg, VA 22802 Phone: 540-564-5100 Fax: 844-305-4862 | |
Dr. Raymond J. Alderfer, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 110 Newman Ave, Harrisonburg, VA 22801 Phone: 540-442-9900 Fax: 540-442-9901 | |
Dr. Mari J Cochran, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 644 University Blvd, Harrisonburg, VA 22801 Phone: 540-564-5100 Fax: 757-579-8573 | |
James Clyde Styron Iv, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1241 N Main St, Harrisonburg, VA 22802 Phone: 540-434-1941 | |
Aamir Mahmood, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 644 University Blvd, Harrisonburg, VA 22801 Phone: 540-564-5100 |